Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13625472 | 0.75 | TOP2A (0.42) | OTUD7BTOP2ATOP2B | |
| SCHEMBL1126303 | 0.70 | TOP2A (0.32) | NPSR1OTUD7BTOP2ATOP2B | |
| SCHEMBL19851165 | 0.69 | OTUD7B (0.36) | OTUD7BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21150733 | 0.68 | NPSR1 (0.33) | NPSR1 | |
| SCHEMBL20414626 | 0.68 | OTUD7B (0.57) | OTUD7BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22172615 | 0.68 | OTUD7B (0.57) | OTUD7BGRIN1GRIN2AGRIN2B | |
| SCHEMBL13879320 | 0.68 | OTUD7B (0.57) | OTUD7BGRIN1GRIN2AGRIN2B | |
| SCHEMBL247639 | 0.67 | — | — | |
| SCHEMBL6806461 | 0.67 | RAB9A (0.31) | — | |
| SCHEMBL19851182 | 0.67 | NEK2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K19 | NPSR1 2761/4885OTUD7B 2216/4885TOP2A 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.